

1 **Alterations in Lipid Profiles in Children with Perinatally Acquired HIV**  
2 **Infection living in Ghana**

3  
4 **Ruth Ayanful-Torgby<sup>1,2\*</sup>, Veronika Shabanova<sup>1,3</sup>, Akosua A. Essuman<sup>2</sup>, Emmanuel Bofo<sup>2</sup>,**  
5 **Linda E. Amoah<sup>2</sup>, Elijah Paintsil<sup>1,4\*</sup>**

6 <sup>1</sup> Department of Pediatrics, Yale School of Medicine, New Haven, CT USA

7 <sup>2</sup> Department of Immunology, Noguchi Memorial Institute for Medical Research, University of  
8 Ghana, Accra, Ghana

9 <sup>3</sup> Department of Biostatistics, Yale School of Public Health, New Haven, CT USA

10 <sup>4</sup> Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine,  
11 Boston, MA USA

12 \*Corresponding authors: [elijahp@bu.edu](mailto:elijahp@bu.edu); [ruthmine2@gmail.com](mailto:ruthmine2@gmail.com)

13

14 **Abstract**

15 Children and adolescents who acquired HIV perinatally and are on lifelong antiretroviral therapy  
16 (ART) are at increased risk of lipid abnormalities, premature atherosclerosis, and early onset  
17 cardiovascular diseases (CVD). Majority of these children reside in sub-Saharan Africa, where  
18 monitoring of lipid profiles is not routine. In this study, we assessed the age dependent prevalence  
19 of dyslipidemia among children and adolescents who acquired HIV in Ghana.

20  
21 In this cross-sectional study we examined lipid profiles of 397 children aged 6 to 18 years.  
22 Dyslipidemia was defined by elevated total cholesterol (TC) ( $\geq 200$  mg/dL) or triglyceride (TG)  
23 levels ( $> 150$  mg/dL) or low-density lipoprotein cholesterol (LDL-C) ( $> 130$  mg/dL) or reduced  
24 high-density lipoprotein cholesterol (HDL-C) ( $< 35$  mg/dL). Dyslipidemia prevalence, by at least  
25 one criterion and for each criterion separately, was compared between age groups 6 - 12 (pre-teen)  
26 and 13 - 18 (teenage) years, as well as by sex.

27  
28 The overall prevalence of dyslipidemia was 42.32%, and by individual criterion was 9.07% using  
29 LDL-C, 11.84% using TC, 15.87% using TG, and 24.00% using HDL-C. Additionally, 5.04%  
30 (n=20) of the participants showed abnormalities across three parameters. Teenagers had a higher  
31 overall prevalence of dyslipidemia (46.75% vs. 39.04%,  $p=0.12$ ). Criterion-based dyslipidemia  
32 prevalence varied across age groups, with TC-based (14.04% vs. 8.88%,  $p=0.12$ ) being higher in  
33 the pre-teen group, while elevated TG-based (20.12% vs. 12.72%,  $p=0.05$ ) and low levels of HDL-  
34 based (28.99% vs. 20.60%,  $p=0.05$ ) were more prevalent in the teenagers. The mean levels of TC  
35 ( $p=0.04$ ) and LDL-C ( $p=0.03$ ) were significantly higher in the pre-teen age groups. Females had

36 nearly twice as high as that of males with prevalence of abnormal LDL-C levels (11.39% vs. 6.67%,  
37 p=0.13).

38

39 This study showed a high prevalence of dyslipidemia among children who acquired HIV perinatally  
40 and are on ART, with age-related variations in lipid profiles. These findings emphasize the  
41 importance of implementing routine monitoring for lipid disorders within this population.

42 **Keywords:** Dyslipidemia, children living with HIV, Lipids profile

43

#### 44 **Introduction**

45 Dyslipidemia, defined as increased low density lipoprotein (LDL-C), high triglycerides (TG) and  
46 cholesterol (TC), and low high density lipoprotein (HDL-C), is the most common metabolic  
47 disorder in individuals living with HIV, regardless of their treatment status <sup>1-3</sup>. Moreover, there are  
48 reports of a significant association between dyslipidemia and the type of antiretroviral therapy  
49 (ART) regimens. For instance, non-nucleoside reverse transcriptase inhibitors (NNRTIs) and  
50 protease inhibitors (PIs) are associated with low HDL-C and hypertriglyceridemia <sup>4,5</sup>. Before  
51 initiation of ART, HIV infection increases triglycerides and decreases TC, HDL-C, and LDL-C <sup>6</sup>.  
52 There are mixed reports on the trends of the various lipids after initiating ART. In a study from  
53 Ethiopia, the prevalence of dyslipidemia was 70% and 58% for ART-experienced and ART-naïve  
54 children, respectively <sup>7</sup>. In this study, the frequency of individuals with low HDL-C and  
55 hypertriglyceridemia were higher among children on ART, however, there were no differences in  
56 total cholesterol and LDL-C <sup>7</sup>.

57

58 Dyslipidemia has been associated with a higher prevalence of cardiovascular diseases (CVD)  
59 among people living with HIV (PLWH) compared to the general population. The risk of CVD  
60 among PLWH is twice as high as those in the general population <sup>8,9</sup>, primarily attributed to  
61 dyslipidemia. Moreover, CVD including conditions like myocardial infarction, manifests among  
62 PLWH a decade or two earlier than in the general population <sup>10</sup>. This trend is particularly significant  
63 in sub-Saharan Africa, where HIV prevalence is high <sup>11</sup>. There is a paucity of studies on CVD in  
64 children living with HIV, although they are susceptible to cardiovascular complications due to  
65 dyslipidemia <sup>12</sup>. In a study of Ugandan children and adolescents living with HIV aged 1 to 17 years,  
66 the prevalence of dyslipidemia was 74%; of those with dyslipidemia, 56% had low HDL-C, 22%  
67 had hypertriglyceridemia, 16% had high LDL-C, and 11% had high total cholesterol levels <sup>190</sup>.  
68 Elevated LDL-C and low HDL-C in children and young adults have been attributed to abnormalities  
69 in the arterial aorta <sup>13</sup>, which serve as precursor to atherosclerosis <sup>14</sup>. Additionally, low HDL-C  
70 levels are associated with inflammation, contributing to insulin resistance and other  
71 cardiometabolic disorders, including metabolic syndrome. Despite the established link between  
72 dyslipidemia and CVD, lipid profiles are not routinely monitored in children living with HIV,  
73 potentially hindering early detection and intervention effort. Considering that alteration in lipid  
74 metabolism is associated with cardiometabolic diseases, an emerging public health problem in most  
75 developing countries, including Ghana, it is imperative to detect precursors of these diseases, such  
76 as dyslipidemia. Early detection of dyslipidemia can help avert related pathologies, such as  
77 myocardial infarction and type 2 diabetes, which are on the rise in young adults living with HIV.  
78  
79 Taken together, dyslipidemia in children living with HIV is an emerging public health concern as  
80 continued lipid abnormalities may contribute to the development of atherosclerosis and other CVD

81 in early adulthood. Given the significant HIV burden in sub-Saharan Africa, a large proportion of  
82 children living with the virus in this region may be at risk of developing CVD associated with  
83 dyslipidemia, which could go unnoticed due to insufficient screening. To address this gap, our study  
84 aimed to assess the prevalence of dyslipidemia and its association with age and sex among  
85 perinatally HIV-infected children receiving ART in Ghana.

86

## 87 **Methods**

### 88 **Study Participants**

89 This multi-center cross-sectional study was conducted from 5<sup>th</sup> January to 28<sup>th</sup> June 2022 among  
90 children and adolescents living with perinatally acquired HIV, aged 6 to 18 years from study  
91 participants were recruited from ten pediatric antiretroviral treatment clinics in ten facilities in  
92 Greater Accra and Eastern regions of Ghana. Details of the study participants have been published  
93 previously <sup>15</sup>. In brief, the study recruited 400 participants from ten pediatric ART treatment clinics  
94 across ten health facilities in Greater Accra and Eastern Regions of Ghana, which share similar  
95 socioeconomic indices. All participants acquired HIV pernatally and had been on uninterrupted  
96 antiretroviral therapy for at least a year, adhering to the national ART treatment guidelines for  
97 children and adolescents. These guidelines prioritize first-line, second-line, or third-line regimens  
98 with appropriate dosages based on ART class and age. We excluded all individuals with viral  
99 hepatitis and TB due to potential interference with lipid/glucose metabolism caused by alternative  
100 medications and regimens <sup>16</sup>. All individuals who were clinically stable and willing to participate  
101 were recruited after being briefed on the study's objectives and procedures. Age-appropriate written  
102 parental informed consent, assent, and consent were obtained prior to participants' enrollment,

103 followed by scheduled sampling procedure (blood draw and urine collection), questionnaire  
104 administration and anthropometric measurements taken at the clinics.

105

### 106 **Ethical Approvals**

107 The study protocol was reviewed and approved by the Institutional Review Boards of the Ghana  
108 Health Service (Protocol # GHS-ERC: 025/09/21) and the Noguchi Memorial Institute for Medical  
109 Research, University of Ghana (Protocol # CPN 015/21-22). Written parental informed consent was  
110 obtained for children aged 6–12 years, while both parental consent and assent were obtained for  
111 participants aged 12–17 years. For participants aged 18 years, individual consent was obtained. All  
112 participants were assured of anonymity and data protection. Research data was stored and used in  
113 compliance with the ethical guidelines approved for the study, ensuring participant protection as  
114 previously reported <sup>15</sup>.

115

### 116 **Data Collection**

117 Detailed information on data collection methods has been published previously <sup>15</sup>. In brief, we  
118 administered questionnaires to participants or their parents/guardians to collect demographic (age,  
119 sex, and residential location), educational (participants' education), and socioeconomic information  
120 (parent or guardian educational level and occupation). Additionally, anthropometric measurements  
121 (upper arm circumference, waist circumference, hip circumference, and neck circumference) were  
122 conducted by a trained member of the study team or health staff.

123

### 124 **Biochemical Parameters**

125 All participants provided 2.5 ml blood samples after an overnight fasting period, before the next

126 morning's blood collection. Serum was separated from 2 mL whole blood samples collected in gel  
127 tubes for subsequent analysis of lipid profile and the remaining 0.5 mL blood used for other  
128 laboratory investigations. The levels of TG, HDL-C, and total TC were measured using a chemical  
129 analyzer (Mindray BS-240, China). LDL-C levels were determined by the Friedewald formula <sup>17</sup>.

130

### 131 **Definitions of Variables**

132 The primary outcome of interest was dyslipidemia, defined as presence of any of the following  
133 parameters: by elevated TC ( $\geq 200$  mg/dL), TG ( $\geq 150$  mg/dL), or LDL-C ( $\geq 130$  mg/dL), or reduced  
134 levels of HDL-C ( $\leq 35$  mg/dL) <sup>18</sup>. Age was stratified into two categorized as 6 - 12 years (pre-teen)  
135 and 13 - 18 years (teenage), while sex was categorized as female or male, based on gender assigned  
136 at birth.

137

### 138 **Statistical Analysis**

139 Categorical variables such as sex, educational level, and caregiver type are summarized as count  
140 (n) and percentage (%), while numeric variables such as age were expressed as means and standard  
141 deviations (SD). Participant characteristics were compared between the two age groups using  
142 Student's t-test or Chi-square statistics for continuous and categorical variables, respectively. We  
143 estimated the prevalence of dyslipidemia, defined as having at least one abnormal parameter, as  
144 well separately based on each of the four lipid parameters (TC, TG, LDL-C, HDL-C), and compared  
145 them based on age group (pre-teen vs. teenage) and sex (male vs. female) using two-samples z-test,  
146 summarizing as counts and percentage. Since we did not power our statistical analysis *a priori*, we  
147 did not rely solely on the strict two-sided alpha level of 0.05 to make conclusions, but coupled our  
148 interpretations with the magnitude of the observed effect sizes. For example, a difference of at least

149 5% in the prevalence of dyslipidimia or a relative difference of at least 1.5 (e.g., the prevalence in  
 150 one group divided by the prevalence in a comparison group), was considered clinically meaningful.  
 151 All statistical analyses were performed using R (version 4.2.2) and GraphPad Prism (version 9.01).

152

## 153 Results

### 154 Characteristics of Study Participants

155 The analysis included 397 of 400 participants with complete lipid profile data on four key lipid  
 156 parameters, i.e., TC, TG, LDL-C, and HDL-C. Participants in the pre-teen age group (6 - 12 years)  
 157 represented 57.43% of the study participants. Distribution of sex variable was similar in the two  
 158 age groups. Variations in BMI measures were evident across the age groups ( $p < 0.0001$ ), with the  
 159 pre-teen group with a mean BMI of 15.65 (SD=3.07) compared to 17.58 (SD=3.48) among the  
 160 teenage group. The mean BMI Z-score values also differed ( $p < 0.0001$ ), with the pre-teen group  
 161 showing a mean negative score of -0.48 (SD=0.66), while the teenage group demonstrated a mean  
 162 positive score of 0.65 (SD=1.02) (**Table 1**).

163

164 **Table 1** Characteristics of Study Participants

165

Variable	Total (N=397)	Age groups	
		Pre-teen (n=228)	Teenage (n=169)
Age, year, Mean (SD)	11.57 (3.49)	9.66 (2.51)	16.94 (3.85)
BMI Mean (SD)	16.94 (3.85)	15.65 (3.07)	17.58 (3.48)
BMI Z-score Mean (SD)	0.00 (0.71)	-0.48 (0.66)	0.65 (1.02)
WHR Mean (SD)	0.83 (0.08)	0.86 (0.07)	0.80 (0.07)
<b>Sex, n (%)</b>			
Female	202 (50.88)	117 (51.32)	85 (50.30)
<b>Education, n (%)</b>			
Basic	354 (89.17)	227 (99.56)	127 (75.15)
Secondary	41 (10.33)	1 (0.44)	40 (23.67)
None	2 (0.50)	0 (0.00)	2 (1.18)
<b>Guardian, n (%)</b>			
Parent	305 (76.83)	181 (79.39)	124 (73.37)
Sibling	12 (3.02)	3 (1.32)	9 (5.34)
Grandparent	31 (7.81)	15 (6.58)	16 (11.24)



Other relative	25 (6.30)	13 (5.70)	12 (7.10)
<sup>a</sup> Others	24 (6.05)	16 (7.02)	8 (4.73)

166 <sup>a</sup>Self or non-relative including living in orphanage Abbreviations: SD=standard deviation, BMI=Body Mass  
 167 Index, WHR=Waist-Height Ratio

168

### 169 Prevalence of Dyslipidemia among the Study Participants

170 One hundred and sixty eight participants had dyslipidemia, representing an overall prevalence of  
 171 42.32% in the study participants. Categorization of dyslipidemia based on the frequency of altered  
 172 levels among the four lipid parameters showed that the majority of participants (n=114, 28.72%)  
 173 had altered levels in only one lipid parameter. Thirty-four individuals (8.56%) showed  
 174 abnormalities in two parameters, while a smaller subset of 20 individuals (5.04%) had abnormalities  
 175 in three parameters. No individual showed dyslipidemia characterized by abnormalities in all four  
 176 lipid parameters. Compared to pre-teens, teenagers had higher prevalence of at least one altered  
 177 parameter of dyslipidemia (46.75% vs. 39.04%, p=0.12; **Table 2**). The prevalence of dyslipidemia  
 178 and the number of altered lipid parameters did not differ between males and females, with the  
 179 exception of proportion of females with abnormal LDL-C levels being nearly twice as high as that  
 180 of males (11.39% vs. 6.67%, p=0.13; Supplementary **Tables S1 and S2**).

181

182 **Table 2** Comparison Frequency of Altered Lipid Parameters between Age Groups/Sex

Altered parameters	Total (n, %)	Age group		p-value
		Pre-teen (n, %)	Teenage (n, %)	
At least 1 ( $\geq 1$ )	168 (42.32)	89 (39.04)	79 (46.75)	0.12
1	114 (28.72)	61 (26.75)	53 (31.40)	0.08
2	34 (8.56)	14 (6.14)	20 (11.80)	
3	20 (5.04)	14 (6.14)	6 (3.60)	
<b>Dyslipidemia (sex)</b>				
Female	83 (41.09)			0.61
Male	85 (43.34)			

183 p-values using a two-sample test for equality of proportions (z-test)

184

185 **Age-Related Disparities in Lipid Profiles**

186 When comparing lipid profiles across age groups (**Table 3**), the teenage group showed higher mean  
 187 TG levels compared to the pre-teen group (p=0.15). LDL-C (p=0.03) and TC (p=0.04) levels were  
 188 lower in the older (teen) age group compared to the younger population. However, the mean HDL-C  
 189 levels between the two age brackets were similar (p=0.28). The prevalence of elevated TG was  
 190 higher in the teenage group (p=0.05). The prevalence of elevated TC was nearly double in the  
 191 younger age group compared to the older age group (p=0.12). Dyslipidemia prevalence based on  
 192 LDL-C was similar in the two age groups (p=0.41). Additionally, the number of individuals with  
 193 low levels of HDL-C was higher in the teenagers than in the pre-teen group (p=0.05).

194

195 **Table 3** Lipid Profile and Comparison Across Age Groups

196

Parameter	Total (N=397)	Age Group		p-value
		Pre-teen (n=228)	Teenage (n=169)	
<b>Mean levels (SD)<sup>b</sup></b>				
TC (mg/dL)	156.07 (45.19)	160.11 (47.09)	150.61 (42.02)	0.04
TG (mg/dL)	96.88 (56.17)	93.37 (53.53)	101.62 (59.50)	0.15
LDL-C (mg/dL)	66.98 (52.15)	71.87 (52.19)	60.39 (51.52)	0.03
HDL-C (mg/dL)	45.05 (16.00)	45.81 (15.26)	44.03 (16.93)	0.28
<b>Dyslipidemia, n (%)<sup>c</sup></b>				
TC (mg/dL)	47 (11.84)	32 (14.04)	15 (8.88)	0.12
TG (mg/dL)	63 (15.87)	29 (12.72)	34 (20.12)	0.05
LDL-C (mg/dL)	36 (9.07)	23 (10.09)	13 (7.69)	0.41
HDL-C (mg/dL)	96 (24.18)	47 (20.61)	49 (28.99)	0.05

197 <sup>b</sup>p-values using Student's t-test, <sup>c</sup> p-values using two-sample z-test. Abbreviation: low density lipoprotein (LDL-C),  
 198 high triglycerides (TG), cholesterol (TC), low high density lipoprotein (HDL-C)

199

## 200 Discussion

201 A concerning increasing trend in the cluster of metabolic disorder components, including  
202 dyslipidemia, has been noted among children living with HIV, predisposing them to an increased  
203 risk to cardiovascular disease <sup>19</sup>. In this study, we examined alterations in four lipid profile  
204 parameters: elevated levels of TC, TG, LDL-C, and low levels of HDL-C, all of which are  
205 acknowledged as significant contributors to CVD risk. Our findings revealed an overall  
206 dyslipidemia prevalence of 42.32% within our study participants, with the prevalences of individual  
207 parameters being 9.07% for LDL-C, 11.84% for TC, 15.87% for TG, and 24.18% for HDL-C. We  
208 observed that compared to the preteens in our study, teenage participants had higher prevalence of  
209 dyslipidemia primarily driven by the elevation in TG and depression in HDL-C. Dyslipidemia  
210 among the pre-teens was characterized by elevated TC. The prevalence of dyslipidemia or levels  
211 of any of the four lipid parameters were not affected by being biologically male or female.

212  
213 The prevalence of dyslipidemia in our study was high, however, a study conducted among South  
214 African children and adolescents living with HIV reported an even higher prevalence of 74% <sup>20</sup>. In  
215 our study cohort, alterations in specific lipid parameters included 9% for elevated LDL-C, 12% for  
216 elevated total cholesterol (TC), 16% for elevated triglycerides (TG), and 24% for low HDL-C; this  
217 is consistent with trends observed in other African studies <sup>21-23</sup>. Among the four lipid parameters  
218 measured, the prevalence of low HDL-C levels was the highest, followed by hypertriglyceridemia.  
219 It is well established that low HDL-C and hypertriglyceridemia are the predominant components of  
220 dyslipidemia in children living with HIV, with prevalence rates in sub-Saharan Africa ranging from  
221 0% to 29% for hypertriglyceridemia <sup>24,25</sup>, and 5% to 72% for low HDL-C <sup>22,25,26</sup>. Similar findings  
222 have been reported in studies of adults living with HIV in Africa <sup>27</sup>, although the prevalence in

223 children tends to be lower, ranging from 6% to 9% for hypertriglyceridemia and 6% to 47% for low  
224 HDL-C<sup>21–23,28</sup>. Notably, a recent study in children living with HIV in Ethiopian reported a much  
225 higher prevalence of 72% for low HDL-C<sup>26</sup>. Outside of Africa, higher rates of low HDL-C have  
226 also been observed among individuals living with HIV in Asian populations. For example, a recent  
227 study found that 47% of Thai youth aged 15 to 24 years had low HDL-C levels, while a study from  
228 India reported that 83% of ART naïve children living with HIV aged 2 to 12 years had low HDL-  
229 C<sup>29,30</sup>. In our study, sex did not significantly influence lipid levels or the prevalence of dyslipidemia,  
230 except for LDL-C, which was more prevalent in females. Our finding is consistent with previous  
231 findings that females usually have higher LDL-C levels than males at puberty<sup>31</sup>. Our results are  
232 consistent with previous research examining dyslipidemia by sex in children living with HIV<sup>32</sup>.  
233 However, in the general population with respect to age or sex, lipid profiles have varied across  
234 studies and populations, particularly when factors such as obesity is considered<sup>33,34</sup>.

235  
236 We observed differences in TG, LDL-C, and TC levels between different age groups. Dyslipidemia  
237 prevalence varied across age groups, with most individuals showing abnormalities in only one  
238 parameter. The younger age group showed much higher levels of the lipid parameters (TC and  
239 LDL-C) than the older group as previously reported eventhough there are conflicting reports based  
240 on the population being studied<sup>35,36</sup>. This difference could be attributed to confounding factors such  
241 as nutrition, viral load, or immune parameters, which were not measured in this study. While the  
242 prevalence of dyslipidemia was high across both age groups, teenagers were more likely to have  
243 altered levels of TG which is consistent with previous studies suggesting an increase in the  
244 prevalence of dyslipidemia during adolescence, possibly attributed to hormonal changes, or  
245 prolonged exposure to HIV and its treatments<sup>3,37</sup>.

246

247 In terms of the frequency of dyslipidemia based on number of alterations in the four lipid parameters,

248 we observed that the majority of participants showed abnormalities in just one lipid parameter as

249 reported in other studies. However, close to 14% of our study participants showed alterations in

250 two or three parameters concurrently. Understanding this variability and the extent of multiple

251 markers of dyslipidemia is crucial for tailored interventional strategies, as different lipid

252 abnormalities may confer varying cardiovascular risks. The presence of multiple-markers of

253 dyslipidemia may not only increase the risk but also predispose individuals to coronary heart

254 disease <sup>38,39</sup>. Several studies have reported that disruptions in multiple lipid parameters significantly

255 elevate CVD risk, with others citing the presence of low HDL-C levels as a key determinant <sup>41,42</sup>.

256 Low HDL-C level is a crucial determinant of cardiovascular risk because HDL-C plays a pivotal

257 role in cholesterol metabolism, inflammation regulation, endothelial function, and the prevention

258 of atherosclerosis. Therefore, the prevalence of dyslipidemia, particularly low HDL-C, warrants

259 routine monitoring of lipid profile in children living with HIV curb CVD sequelae in their adulthood.

260

261 Although our study provided valuable insights on dyslipidemia in children living with HIV in

262 Ghana, there were limitations that need to be acknowledged. First, missing variables of HIV

263 diseases status such as treatment history, ART regimen, viral load, and CD4 count. Second, the

264 cross-sectional design and lack of HIV-specific factors could introduce bias and influence

265 dyslipidemia prevalence estimates and other risk factors, as previously acknowledged <sup>15</sup>. Third, the

266 study design limits the ability to draw causal inferences. Future longitudinal studies are needed to

267 validate our findings.

268

269 In conclusion, our results show a high prevalence of dyslipidemia among perinatally children living  
270 with in Ghana. Low HDL-C levels, a pivotal predictor of CVD risk and inflammation, was the  
271 prevalent parameter among individuals with dyslipidemia in our study. This highlights the need for  
272 routine monitoring of lipid profile of children living with HIV and proactive management to prevent  
273 CVDs in adulthood. Furthermore, there is urgent need for further research into the etiopathogenesis  
274 of rising dyslipidemia and evolving epidemic of cardiometabolic diseases in children living with  
275 HIV, particularly in sub-Saharan Africa.

276

### 277 **Author Contributions**

278 Conceived and designed the experiments: RAT, EP. Data Collection: RAT, AAY, EB. Performed  
279 the experiments: RAT, AAY, EB. Analyzed the data: RAT. Original Draft: RAT. Reviewed  
280 manuscript drafts: RAT, VS, LEA, EP.

281

### 282 **Acknowledgements**

283 We thank the study participants, their parents or guardians, ART clinic staff, and the Ghana  
284 National AIDS Control Program for their cooperation and support. This study received support  
285 from the Fogarty International Center and the National Institute of Alcohol Abuse and Alcoholism  
286 (NIH D43 TW011526).

287

### 288 **Conflicts of Interest**

289 The authors declare no conflicts of interest.

290

291 **Reference**

- 292 1. the PREDICT study group *et al.* High Prevalence of Lipid Abnormalities among Antiretroviral-  
293 Naive HIV-Infected Asian Children with Mild-To-Moderate Immunosuppression. *Antivir. Ther.*  
294 **16**, 1351–1355 (2011).
- 295 2. Chantry, C. J. *et al.* Lipid and Glucose Alterations in HIV-Infected Children Beginning or  
296 Changing Antiretroviral Therapy. *Pediatrics* **122**, e129–e138 (2008).
- 297 3. Trevillyan, J. M. *et al.* Changes in plasma lipidome following initiation of antiretroviral therapy.  
298 *PLOS ONE* **13**, e0202944 (2018).
- 299 4. Ishaya, A. & Olukemi, I. Prevalence of metabolic syndrome in HIV-infected and Non-HIV  
300 infected Nigerian children in Jos. *J. Med. Trop.* **22**, 8 (2020).
- 301 5. McComsey, G. A. *et al.* Increased carotid intima media thickness and cardiac biomarkers in  
302 HIV infected children. *AIDS* **21**, 921–927 (2007).
- 303 6. Sprinz, E., Lazzaretti, R. K., Kuhmmer, R. & Ribeiro, J. P. Dyslipidemia in HIV-infected  
304 individuals. *Braz. J. Infect. Dis.* **14**, 575–588 (2010).
- 305 7. Tadesse, F. G. *et al.* The Relative Contribution of Symptomatic and Asymptomatic Plasmodium  
306 vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic  
307 Setting in Ethiopia. *Clin. Infect. Dis.* **66**, 1883–1891 (2018).
- 308 8. Shah, A. S. V. *et al.* Global Burden of Atherosclerotic Cardiovascular Disease in People Living  
309 With HIV: Systematic Review and Meta-Analysis. *Circulation* **138**, 1100–1112 (2018).
- 310 9. Alonso, A. *et al.* HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a  
311 Large Healthcare Database. *J. Am. Heart Assoc.* **8**, e012241 (2019).
- 312 10. Freiberg, M. S. *et al.* HIV infection and the risk of acute myocardial infarction. *JAMA Intern.*  
313 *Med.* **173**, 614–622 (2013).

- 314 11. Shah, A. S. V. *et al.* Global Burden of Atherosclerotic Cardiovascular Disease in People Living  
315 With HIV: Systematic Review and Meta-Analysis. *Circulation* **138**, 1100–1112 (2018).
- 316 12. Boccard, F. *et al.* HIV and Coronary Heart Disease. *J. Am. Coll. Cardiol.* **61**, 511–523 (2013).
- 317 13. Sainz, T. *et al.* Cardiac Function in Vertically HIV-infected Children and Adolescents in the  
318 Era of Highly Active Antiretroviral Therapy. *Pediatr. Infect. Dis. J.* **34**, e125–e131 (2015).
- 319 14. Hao, W. & Friedman, A. The LDL-HDL Profile Determines the Risk of Atherosclerosis: A  
320 Mathematical Model. *PLoS ONE* **9**, e90497 (2014).
- 321 15. Ayanful-Torgby, R. *et al.* High prevalence of impaired glucose metabolism among children and  
322 adolescents living with HIV in Ghana. *HIV Med.* hiv.13614 (2024) doi:10.1111/hiv.13614.
- 323 16. National AIDS/STI Control Programme, Ghana Health Service. Consolidated Guidelines for  
324 HIV Care in Ghana Test, Treat & Track. (2019).
- 325 17. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the Concentration of Low-  
326 Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge.  
327 *Clin. Chem.* **18**, 499–502 (1972).
- 328 18. Kavey, R.-E. W. *et al.* American Heart Association guidelines for primary prevention of  
329 atherosclerotic cardiovascular disease beginning in childhood. *Circulation* **107**, 1562–1566  
330 (2003).
- 331 19. Kelesidis, T. & Currier, J. S. Dyslipidemia and Cardiovascular Risk in Human  
332 Immunodeficiency Virus Infection. *Endocrinol. Metab. Clin. North Am.* **43**, 665–684 (2014).
- 333 20. Nampijja, D. Dyslipidemia and its Correlates among HIV Infected Children on HAART  
334 Attending Mbarara Regional Referral Hospital. *Int. Clin. Pathol. J.* **4**, (2017).



- 335 21. Musiime, V. *et al.* Anthropometric Measurements and Lipid Profiles to Detect Early  
336 Lipodystrophy in Antiretroviral Therapy Experienced HIV-Infected Children in the Chapas-3  
337 Trial. *Antivir. Ther.* **19**, 269–276 (2014).
- 338 22. Arpadi, S. *et al.* Metabolic abnormalities and body composition of HIV-infected children on  
339 Lopinavir or Nevirapine-based antiretroviral therapy. *Arch. Dis. Child.* **98**, 258–264 (2013).
- 340 23. Innes, S., Abdullah, K. L., Haubrich, R., Cotton, M. F. & Browne, S. H. High Prevalence of  
341 Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on  
342 Antiretroviral Therapy. *Pediatr. Infect. Dis. J.* **35**, e1–e7 (2016).
- 343 24. Piloya, T., Bakeera-Kitaka, S., Kekitiinwa, A. & Kanya, M. R. Lipodystrophy among HIV-  
344 infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross  
345 sectional study. *J. Int. AIDS Soc.* **15**, (2012).
- 346 25. Bwakura-Dangarembizi, M. *et al.* Prevalence of Lipodystrophy and Metabolic Abnormalities  
347 in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy. *Pediatr.*  
348 *Infect. Dis. J.* **34**, e23–e31 (2015).
- 349 26. Ambisa Lamesa, T. *et al.* Dyslipidemia and Nutritional Status of HIV-Infected Children and  
350 Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training  
351 Center of Jimma Medical Center. *HIVAIDS Auckl. NZ* **15**, 537–547 (2023).
- 352 27. Naidu, S., Ponnampalvanar, S., Kamaruzzaman, S. B. & Kamarulzaman, A. Prevalence of  
353 Metabolic Syndrome Among People Living with HIV in Developing Countries: A Systematic  
354 Review. *AIDS Patient Care STDs* **31**, 1–13 (2017).
- 355 28. Kisitu, G. *et al.* High prevalence of low high-density lipoprotein cholesterol and insulin  
356 resistance among children and adolescents living with HIV in Uganda: harbinger for metabolic  
357 syndrome? *HIV Med.* **25**, 262–275 (2024).

- 358 29. Aupibul, L., Namwongprom, S., Sudjaritruk, T. & Ounjaijean, S. Metabolic syndrome,  
359 biochemical markers, and body composition in youth living with perinatal HIV infection on  
360 antiretroviral treatment. *PLOS ONE* **15**, e0230707 (2020).
- 361 30. Padmapriyadarsini, C. *et al.* High Prevalence of Lipid Abnormalities and Insulin Resistance  
362 Among Antiretroviral Naïve HIV-infected Children in India. *Pediatr. Infect. Dis. J.* **37**, 253–  
363 257 (2018).
- 364 31. Dobashi, K. Changes in Serum Cholesterol in Childhood and its Tracking to Adulthood. *J.*  
365 *Atheroscler. Thromb.* **29**, 5–7 (2022).
- 366 32. Alves Junior, C. A. S. *et al.* Association between lipid and glycemic profile and total body and  
367 trunk fat in children and adolescents diagnosed with HIV+. *Clin. Nutr. ESPEN* **53**, 7–12 (2023).
- 368 33. Baig, Z. A. *et al.* Risk Analysis and Assessment of Lipid Abnormalities as the Earliest  
369 Complication in Newly Diagnosed Diabetic and Non-Diabetic Individuals of a Local  
370 Population. *Healthcare* **10**, 2308 (2022).
- 371 34. Huang, Y. *et al.* Lipid profiling identifies modifiable signatures of cardiometabolic risk in  
372 children and adolescents with obesity. *Nat. Med.* (2024) doi:10.1038/s41591-024-03279-x.
- 373 35. Webber, L. S., Srinivasan, S. R., Wattigney, W. A. & Berenson, G. S. Tracking of Serum Lipids  
374 and Lipoproteins from Childhood to Adulthood. *Am. J. Epidemiol.* **133**, 884–899 (1991).
- 375 36. EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH  
376 AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert Panel on Integrated  
377 Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents:  
378 Summary Report. *Pediatrics* **128**, S213–S256 (2011).
- 379 37. Schienkiewitz, A. *et al.* Age, maturation and serum lipid parameters: findings from the German  
380 Health Survey for Children and Adolescents. *BMC Public Health* **19**, 1627 (2019).

- 381 38. Asghari, S. *et al.* Single and mixed dyslipidaemia in Canadian primary care settings: findings  
382 from the Canadian primary care sentinel surveillance network database. *BMJ Open* **5**, e007954  
383 (2015).
- 384 39. Achila, O. O. *et al.* A community based cross sectional study on the prevalence of dyslipidemias  
385 and 10 years cardiovascular risk scores in adults in Asmara, Eritrea. *Sci. Rep.* **12**, 5567 (2022).
- 386 40. Bartlett, J. *et al.* Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular  
387 Disease Risk Factor? New Insights From the Framingham Offspring Study. *Circ. Cardiovasc.*  
388 *Qual. Outcomes* **9**, 206–212 (2016).
- 389 41. März, W. *et al.* HDL cholesterol: reappraisal of its clinical relevance. *Clin. Res. Cardiol.* **106**,  
390 663–675 (2017).
- 391 42. Magnoni, M. *et al.* Predictive value of HDL function in patients with coronary artery disease:  
392 relationship with coronary plaque characteristics and clinical events. *Ann. Med.* **54**, 1036–1046  
393 (2022).
- 394